A Combination Study With Ridaforolimus (MK8669) and Dalotuzumab (MK0646) in Patients With Advanced Cancer (8669-004)
This study has been completed.
Sponsor:
Merck
Collaborator:
Ariad Pharmaceuticals
Information provided by:
Merck
ClinicalTrials.gov Identifier:
NCT00730379
First received: August 6, 2008
Last updated: December 17, 2010
Last verified: December 2010
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Study Status: | This study has been completed. |
|---|---|
| Study Completion Date: | November 2010 |
| Primary Completion Date: | November 2010 (Final data collection date for primary outcome measure) |